Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. This growth was driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. The drug recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%.
The company also announced that TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. Coverage is expected to reach approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. This expansion in coverage is likely to further boost sales and market penetration.
In addition to commercial progress, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This provides a solid runway for ongoing commercial activities and clinical development.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years, and its commercial success is a key milestone for the company. The CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.
The company is also exploring the potential of TONMYA in other indications. Phase 2 clinical trials are evaluating its use in major depressive disorder and acute stress disorder. Additionally, Tonix's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, the company is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
These developments underscore Tonix's commitment to addressing significant unmet medical needs and its strategic focus on commercial execution and pipeline advancement. The strong revenue growth and promising pipeline position the company for continued progress.
For more information, visit the full press release at https://ibn.fm/6Yytj.
